Market Research Logo

Global Epigenomic Market Forecast 2018-2026

Global Epigenomic Market Forecast 2018-2026

KEY FINDINGS

The global epigenomics market is forecasted to progress at 18.25% CAGR between the projected years of 2018-2026. Factors such as the high prevalence of cancer and other chronic diseases, better funding for research & development and increase in the demand for personalized medicine are driving this market’s growth.

MARKET INSIGHTS

The global epigenomics market is classified on the basis of technology, products, applications, area and segments. DNA methylation, histone methylation & acetylation and MicroRNA modification are the technologies deployed in this market. Epigenomics product segment includes reagents, kits, instruments, enzymes and services. The market finds its application in oncology and non-oncology areas. Diagnosis, drug discovery, therapy optimization and prognosis are the areas in which the global epigenomics market deals in. Market by segments is classified into epigenetic diagnostics, personalized medicines, epigenetic therapies and biomarkers.

REGIONAL INSIGHTS

Regional segmentation of the global epigenomics market is done into North America, Europe, Asia-Pacific and rest of the world. North America currently accounts for the highest revenue share in the epigenomics market. The region is witnessing increasing collaborations between the big pharma companies to innovate and produce technologically advanced products.

COMPETITIVE INSIGHTS

Companies making progress in the epigenomics domain include Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, Bayer Ag, Bio Vision, Celgene Corp, Epigenomics Ag, Epigentek, Glaxosmithkline, Illumina Inc, Johnson & Johnson, Laboratory Corp Of America Holdings, Merck Sharp & Dohme, Naturewise Biotech & Medicals Corp, Novartis Pharma Ag, Orchid Chemicals & Pharmaceuticals Limited, Tbg Diagnostics Limited, Rubicon Genomics, and Roche Holding Ag.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1 North America Leads The Market By Capturing The Largest Revenue Share
3.2.2 Asia Pacific Is Anticipated To Be The Most Dynamic Regional Market
3.2.3 Reagents Form A Major Part Of Epigenomic Market By Product
3.2.4 Epigenetics Diagnosis Is A Major Part Of Epigenomic Market, And Personalized Medicines Is Showing A Dynamic Growth
3.2.5 Oncology Is The Primary Application While Non-oncology Is Showing A Better Growth
4. Market Dynamics
4.1. Market Definition & Scope
4.2. Market Drivers
4.2.1. Advancement In The Prevalence Of Cancer And Other Chronic Diseases
4.2.2. Rise In The Ageing Population
4.2.3. Decline In The Sequencing Costs And Time
4.2.4. Escalation In Funding For Research & Development
4.2.5. Need For Better Cancer Therapies
4.2.6. Growth In Personalized Medicine
4.2.7. Increasing Importance Of Epigenetic Technology
4.3. Market Restraints
4.3.1 Inefficiency In Identification And Validation Of Biomarker
4.3.2 Presence Of Complex Regulatory Framework
4.3.3 Lack Of Reimbursement Provision In Insurance For Epigenomic
4.4. Market Opportunities
4.4.1 Increasing Awareness About Epigenomic
4.4.2 Advancement Of Potential In Emerging Markets
4.4.3 Expanding Applications Of Epigenetics In Personalized Medicine And Targeted Therapy
4.4.4 Use Of Epigenomics In Non-oncology Applications
4.5. Market Challenges
4.5.1 Scarcity Of Trained Professionals
4.5.2 High Cost Of Instruments And Consumables
5. Market By Product
5.1. Reagents
5.2. Kits
5.3. Instruments
5.4. Enzymes
5.5. Services
6. Market By Technology
6.1. Dna Methylation
6.2. Histone Methylation & Acetylation
6.3. Microrna Modification
7. Market By Application
7.1. Oncology
7.1.1. Dna Methyltransferase Inhibitors
7.1.2. Histone Deacetylase Inhibitors
7.2. Non-oncology
8. Market By Application Area
8.1. Diagnosis
8.2. Drug Discovery
8.3. Therapy Optimization
8.4. Prognosis
9. Market By Segment
9.1. Epigenetic Diagnosis
9.1.1. Cancer
9.1.2. Neuro
9.1.2.1. Mental Retardation
9.1.2.2. Alzheimer’s Disease
9.1.2.3. Depression
9.1.2.4. Other
9.1.3. Cardiovascular
9.1.3.1. Vascular Disease
9.1.3.2. Heart Failure
9.1.3.3. Others
9.1.4. Inflammatory & Autoimmune Disease
9.1.4.1. Rheumatoid Arthritis
9.1.4.2. Diabetes
9.1.4.3. Lupus
9.1.4.4. Multiple Sclerosis
9.1.4.5. Inflammatory Bowel Diseases
9.1.5. R&D
9.1.5.1. Dna Methylation In Cancer Detection
9.1.5.2. Identification Of Epigenetic Biomarkers For Diagnosis And Prediction
9.1.5.3. Mechanisms Of Epigenetic Gene Silencing
9.2. Personalized Medicine
9.2.1. Cancer Treatment
9.2.1.1. Lung Cancer
9.2.1.2. Solid Cancers
9.2.1.3. Gastric Cancer
9.2.1.4. Hematological Cancers
9.2.1.5. Others
9.2.2. Neurological Disorders
9.2.2.1. Mental Retardation
9.2.2.2. Huntington’s Disease
9.2.2.3. Parkinson’s Disease
9.2.2.4. Alzheimer’s Disease
9.2.2.5. Depression
9.2.3. Cvd
9.2.4. Others
9.2.4.1. Rheumatoid Arthritis
9.2.4.2. Diabetes
9.2.4.3. Myelodysplastic Syndromes
9.2.4.4. Multiple Sclerosis
9.2.4.5. Obesity
9.2.4.6. Inflammatory Bowel Diseases
9.2.4.7. Lupus
9.2.4.8. Other
9.3. Epigenetic Therapies
9.4. Biomarkers
9.4.1. Dna Methylation For Cancer Detection
9.4.2. Histonic Modification As Biomarker In Cancer Detection
9.4.2.1. Histone Methylation
9.4.2.2. Histone Acetylation
9.4.3. Noncoding Rnas
9.4.4. Mirnas
9.4.5. Chromatin Remodeling
10. Key Analytics
10.1. Porter’s Five Force Model
10.1.1. Threat Of New Entrants
10.1.2. Threat Of Substitute
10.1.3. Bargaining Power Of Suppliers
10.1.4. Bargaining Power Of Buyers
10.1.5. Threat Of Competitive Rivalry
10.2. Opportunity Matrix
10.3. Vendor Landscape
11. Geographical Analysis
11.1. North America
11.1.1. United States
11.1.2. Canada
11.2. Europe
11.2.1. Germany
11.2.2. United Kingdom
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest Of Europe
11.3. Asia Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. South Korea
11.3.5. Rest Of Asia Pacific
11.4. Rest Of World
11.4.1. Latin America
11.4.2. Middle East And Africa
12. Company Profiles
12.1. Abbott Laboratories
12.2. Affymetrix
12.3. Agilent Technologies
12.4. Astellas Pharmaceuticals
12.5. Bayer Ag
12.6. Bio Vision
12.7. Celgene Corp.
12.8. Epigenomics Ag
12.9. Epigentek
12.10. Glaxosmithkline
12.11. Illumina Inc.
12.12. Johnson & Johnson
12.13. Laboratory Corp. Of America Holdings
12.14. Merck Sharp & Dohme
12.15. Naturewise Biotech & Medicals Corp.
12.16. Novartis Pharma Ag
12.17. Orchid Chemicals & Pharmaceuticals Limited
12.18. Tbg Diagnostics Limited
12.19. Rubicon Genomics
12.20. Roche Holding Ag
Table List
Table 1 Global Epigenomic Market, By Geography, 2018-2026, (In $ Ten Thousand)
Table 2 Global Epigenomic Market, By Product, 2018-2026, (In $ Ten Thousand)
Table 3 Global Reagents Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 4 Global Kits Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 5 Global Instruments Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 6 Global Enzymes Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 7 Global Services Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 8 Global Epigenomic Market, By Technology, 2018-2026, (In $ Ten Thousand)
Table 9 Global Dna Methylation Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 10 Global Histone Methylation And Acetylation Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 11 Global Micro-rna Modification Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 12 Global Epigenomic Market, By Application, 2018-2026, (In $ Ten Thousand)
Table 13 Global Epigenomics Application Market, By Oncology, 2018-2026 (In $ Ten Thousand)
Table 14 Global Oncology Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 15 Global Dna Methyltransferase Inhibitors Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 16 Global Histone Deacetylase Inhibitors Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 17 Global Non-oncology Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 18 Global Epigenomic Market, By Application Area, 2018-2026, (In $ Ten Thousand)
Table 19 Global Diagnosis Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 20 Global Drug Discovery Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 21 Global Therapy Optimization Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 22 Global Prognosis Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 23 Global Epigenomic Market, By Segment, 2018-2026, (In $ Ten Thousand)
Table 24 Global Epigenomic Market, By Epigenetic Diagnosis, 2018-2026 (In $ Ten Thousand)
Table 25 Global Epigenetic Diagnosis Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 26 Global Epigenetic Diagnosis Market, By Neuro, 2018-2026, (In $ Ten Thousand)
Table 27 Global Epigenetic Diagnosis Market, By Cardiovascular, 2018-2026, (In $ Ten Thousand)
Table 28 Global Epigenetic Diagnosis Market, By Inflammatory & Autoimmune Disease, 2018-2026, (In $ Ten Thousand)
Table 29 Global Epigenetic Diagnosis Market, By R&D, 2018-2026, (In $ Ten Thousand)
Table 30 Global Epigenomic Market, By Personalized Medicine, 2018-2026, (In $ Ten Thousand)
Table 31 Global Personalized Medicine Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 32 Global Personalized Medicine Market, By Cancer Treatment, 2018-2026, (In $ Ten Thousand)
Table 33 Global Personalized Medicine Market, By Neurological Disorders, 2018-2026 (In $ Ten Thousand)
Table 34 Global Personalized Medicine Market, By Others, 2018-2026 (In $ Ten Thousand)
Table 35 Global Epigenetic Therapies Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 36 Global Epigenomics Market, By Biomarkers, 2018-2026 (In $ Ten Thousand)
Table 37 Global Biomarkers Market, By Region, 2018-2026, (In $ Ten Thousand)
Table 38 Opportunity Matrix
Table 39 Vendor Landscape
Table 40 Global Epigenomic Market, By Geography, 2018-2026, (In $ Ten Thousand)
Table 41 North America Epigenomic Market, By Country, 2018-2026 (In $ Ten Thousand)
Table 42 Europe Epigenomic Market, By Country, 2018-2026 (In $ Ten Thousand)
Table 43 Asia Pacific Epigenomic Market, By Country, 2018-2026 (In $ Ten Thousand)
Figure List
Figure 1 Global Epigenomic Market Share, By Segment 2017 & 2026 (%)
Figure 2 North America Epigenomic Market, 2018 - 2026 (In $ Billion)
Figure 3 Asia Pacific Revenue Estimation ($ Ten Thousand)
Figure 4 Reagents Estimated Revenue ($ten Thousand)
Figure 5 Epigenetic Diagnosis Estimated Revenue ($ Ten Thousand
Figure 6 Personalized Medicines Estimated Revenue ($ Ten Thousand)
Figure 7 Oncology Revenue Estimation ($ Ten Thousand)
Figure 8 Non-oncology Revenue Estimation ($ Ten Thousand)
Figure 9 Global Epigenomic Market, By Reagents, 2018-2026, (In $ Ten Thousand)
Figure 10 Global Epigenomic Market, By Kits, 2018-2026, (In $ Ten Thousand)
Figure 11 Global Epigenomic Market, By Instruments, 2018-2026, (In $ Ten Thousand)
Figure 12 Global Epigenomic Market, By Enzymes, 2018-2026, (In $ Ten Thousand)
Figure 13 Global Epigenomic Market, By Services, 2018-2026, (In $ Ten Thousand)
Figure 14 Global Epigenomic Market, By Dna Methylation, 2018-2026, (In $ Ten Thousand)
Figure 15 Global Epigenomic Market, By Histone Methylation And Acetylation, 2018-2026, (In $ Ten Thousand)
Figure 16 Global Epigenomic Market, By Micro-rna Modification, 2018-2026, (In $ Ten Thousand)
Figure 17 Global Epigenomic Market, By Oncology, 2018-2026, (In $ Ten Thousand)
Figure 18 Global Epigenomic Market, By Dna Methyltransferase Inhibitors, 2018-2026, (In $ Ten Thousand)
Figure 19 Global Epigenomic Market, By Histone Deacetylase Inhibitors, 2018-2026, (In $ Ten Thousand)
Figure 20 Global Epigenomic Market, By Non-oncology, 2018-2026, (In $ Ten Thousand)
Figure 21 Global Epigenomic Market, By Diagnosis, 2018-2026, (In $ Ten Thousand)
Figure 22 Global Epigenomic Market, By Drug Discovery, 2018-2026, (In $ Ten Thousand)
Figure 23 Global Epigenomic Market, By Therapy Optimization, 2018-2026, (In $ Ten Thousand)
Figure 24 Global Epigenomic Market, By Prognosis, 2018-2026, (In $ Ten Thousand)
Figure 25 Global Epigenomic Market, By Epigenetic Diagnosis, 2018-2026, (In $ Ten Thousand)
Figure 26 Global Epigenomic Market, By Epigenetic Diagnosis-cancer, 2018-2026, (In $ Ten Thousand)
Figure 27 Global Epigenomic Market, By Neuro-mental Retardation, 2018-2026, (In $ Ten Thousand)
Figure 28 Global Epigenomic Market, By Neuro- Alzheimer’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 29 Global Epigenomic Market, By Neuro- Depression, 2018-2 026, (In $ Ten Thousand)
Figure 30 Global Epigenomic Market, By Neuro- Other, 2018-2026, (In $ Ten Thousand)
Figure 31 Global Epigenomic Market, By Cardiovascular-vascular Disease, 2018-2026, (In $ Ten Thousand)
Figure 32 Global Epigenomic Market, By Cardiovascular- Heart Failure, 2018-2026, (In $ Ten Thousand)
Figure 33 Global Epigenomic Market, By Cardiovascular- Others, 2018-2026, (In $ Ten Thousand)
Figure 34 Global Epigenomic Market, By Rheumatoid Arthritis, 2018-2026, (In $ Ten Thousand)
Figure 35 Global Epigenomic Market, By Diabetes, 2018-2026, (In $ Ten Thousand)
Figure 36 Global Epigenomic Market, By Lupus, 2018-2026, (In $ Ten Thousand)
Figure 37 Global Epigenomic Market, By Multiple Sclerosis, 2018-2026, (In $ Ten Thousand)
Figure 38 Global Epigenomic Market, By Inflammatory Bowel Diseases, 2018-2026, (In $ Ten Thousand)
Figure 39 Global Epigenomic Market, By Dna Methylation In Cancer Detection, 2018-2026, (In $ Ten Thousand)
Figure 40 Global Epigenomic Market, By Identification Of Epigenetic Biomarkers For Diagnosis And Prediction, 2018-2026, (In $ Ten Thousand)
Figure 41 Global Epigenomic Market, By Mechanisms Of Epigenetic Gene Silencing, 2018-2026, (In $ Ten Thousand)
Figure 42 Global Epigenomic Market, By Cancer Treatment, 2018-2026, (In $ Ten Thousand)
Figure 43 Global Epigenomic Market, By Lung Cancer, 2018-2026, (In $ Ten Thousand)
Figure 44 Global Epigenomic Market, By Solid Cancers, 2018-2026, (In $ Ten Thousand)
Figure 45 Global Epigenomic Market, By Gastric Cancer, 2018-2026, (In $ Ten Thousand)
Figure 46 Global Epigenomic Market, By Hematological Cancers, 2018-2026, (In $ Ten Thousand)
Figure 47 Global Epigenomic Market, By Others, 2018-2026, (In $ Ten Thousand)
Figure 48 Global Epigenomic Market, By Mental Retardation, 2018-2026, (In $ Ten Thousand)
Figure 49 Global Epigenomic Market, By Huntington’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 50 Global Epigenomic Market, By Parkinson’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 51 Global Epigenomic Market, By Alzheimer’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 52 Global Epigenomic Market, By Depression, 2018-2026, (In $ Ten Thousand)
Figure 53 Global Epigenomic Market, By Cvd, 2018-2026, (In $ Ten Thousand)
Figure 54 Global Epigenomic Market, By Rheumatoid Arthritis, 2018-2026, (In $ Ten Thousand)
Figure 55 Global Epigenomic Market, By Diabetes, 2018-2026, (In $ Ten Thousand)
Figure 56 Global Epigenomic Market, By Myelodysplastic Syndromes, 2018-2026, (In $ Ten Thousand)
Figure 57 Global Epigenomic Market, By Multiple Sclerosis, 2018-2026, (In $ Ten Thousand)
Figure 58 Global Epigenomic Market, By Obesity, 2018-2026, (In $ Ten Thousand)
Figure 59 Global Epigenomic Market, By Inflammatory Bowel Diseases, 2018-2026, (In $ Ten Thousand)
Figure 60 Global Epigenomic Market, By Lupus, 2018-2026, (In $ Ten Thousand)
Figure 61 Global Epigenomic Market, By Other, 2018-2026, (In $ Ten Thousand)
Figure 62 Global Epigenomic Market, By Epigenetic Therapies, 2018-2026, (In $ Ten Thousand)
Figure 63 Global Epigenomic Market, By Biomarkers, 2018-2026, (In $ Ten Thousand)
Figure 64 Global Epigenomic Market, By Dna Methylation, 2018-2026, (In $ Ten Thousand)
Figure 65 Global Epigenomic Market, By Histonic Modification, 2018-2026, (In $ Ten Thousand)
Figure 66 Global Epigenomic Market, By Histone Methylation, 2018-2026, (In $ Ten Thousand)
Figure 67 Global Epigenomic Market, By Histone Acetylation, 2018-2026, (In $ Ten Thousand)
Figure 68 Global Epigenomic Market, By Noncoding Rnas, 2018-2026, (In $ Ten Thousand)
Figure 69 Global Epigenomic Market, By Mirnas, 20 18-2026, (In $ Ten Thousand)
Figure 70 Global Epigenomic Market, By Chromatin Remodeling, 2018-2026, (In $ Ten Thousand)
Figure 71 Porter’s Five Force Model
Figure 72 Global Epigenomic Market, Regional Outlook, 2018-2026, (In $ Ten Thousand)
Figure 73 United States Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 74 Canada Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 75 Germany Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 76 United Kingdom Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 77 France Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 78 Italy Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 79 Spain Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 80 Rest Of Europe Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 81 China Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 82 Japan Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 83 India Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 84 South Korea Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 85 Rest Of Asia Pacific Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 86 Latin America Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 87 Middle East And Africa Epigenomic Market, 2018-2026 (In $ Ten Thousand)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report